{"id":"loteprednol-lotemax","safety":{"commonSideEffects":[{"rate":null,"effect":"Elevated intraocular pressure"},{"rate":null,"effect":"Ocular irritation"},{"rate":null,"effect":"Conjunctival hyperemia"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Loteprednol is a soft corticosteroid designed to reduce inflammation and immune-mediated responses while minimizing systemic absorption and associated side effects. It binds to glucocorticoid receptors in ocular tissues, inhibiting the production of inflammatory mediators and reducing edema, erythema, and immune cell infiltration. The ester structure allows rapid metabolism, reducing the risk of elevated intraocular pressure compared to traditional corticosteroids.","oneSentence":"Loteprednol is a corticosteroid that suppresses inflammatory and immune responses in the eye by binding to glucocorticoid receptors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:53:12.766Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammation and pain following ocular surgery"},{"name":"Seasonal allergic conjunctivitis"},{"name":"Uveitis"},{"name":"Dry eye disease"}]},"trialDetails":[{"nctId":"NCT07496060","phase":"PHASE4","title":"Loteprednol Etabonate Versus Prednisolone Acetate for Anterior Chamber Granulomas","status":"COMPLETED","sponsor":"Fayoum University","startDate":"2025-08-10","conditions":"Anterior Chamber Granulomatous Uveitis","enrollment":66},{"nctId":"NCT05542381","phase":"NA","title":"The Role of Loteprednol in Reducing Post-Intravitreal Injection Related Pain","status":"COMPLETED","sponsor":"Virginia Polytechnic Institute and State University","startDate":"2022-12-22","conditions":"Age-Related Macular Degeneration","enrollment":64},{"nctId":"NCT07090044","phase":"PHASE4","title":"Comparing Post-intravitreal Injection Pain Scores Using Loteprednol, Bromfenac Sodium, and Artificial Tears Over a 24-hour Period","status":"COMPLETED","sponsor":"Retina Research Institute, LLC","startDate":"2021-08-20","conditions":"Vein Occlusion, Macular Degeneration Choroidal Neovascularization, Macular Edema","enrollment":77},{"nctId":"NCT04418999","phase":"EARLY_PHASE1","title":"Safety and Efficacy of Intracanalicular Dexamethasone Compared to Loteprednol Etabonate in Patients With Keratoconus","status":"COMPLETED","sponsor":"Illinois College of Optometry","startDate":"2020-09-01","conditions":"Keratoconus, Dry Eye, Allergy","enrollment":36},{"nctId":"NCT05136443","phase":"PHASE4","title":"Loteprednol Etabonate 0.25% for Prevention of Cornea Transplant Rejection","status":"COMPLETED","sponsor":"Price Vision Group","startDate":"2021-11-23","conditions":"Corneal Endothelial Dystrophy, Corneal Edema","enrollment":70},{"nctId":"NCT02120079","phase":"PHASE4","title":"The Utility of IVCM to Assess Cellular Response and Efficacy of Long-term Topical Steroid Treatment in Patients With DED","status":"COMPLETED","sponsor":"Tufts Medical Center","startDate":"2014-02","conditions":"Dry Eye Disease","enrollment":37},{"nctId":"NCT04555694","phase":"PHASE4","title":"Comparing Treatment of Dry Eye With Intracanalicular Dexamethasone, Restasis, and/or Lotemax","status":"COMPLETED","sponsor":"Thomas Chester, OD","startDate":"2020-10-01","conditions":"Dry Eye","enrollment":30},{"nctId":"NCT04521140","phase":"PHASE4","title":"Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Corneal Transplant Surgery","status":"COMPLETED","sponsor":"Nicole Fram M.D.","startDate":"2020-10-16","conditions":"Corneal Edema, Corneal Defect, Corneal Transplant","enrollment":36},{"nctId":"NCT05322148","phase":"PHASE3","title":"Cyclosporine 0.1% / Loteprednol 0.2% Effect on Anterior Segment Normalization","status":"COMPLETED","sponsor":"Research Insight LLC","startDate":"2022-06-03","conditions":"Dry Eye","enrollment":59},{"nctId":"NCT05353101","phase":"PHASE1","title":"Cyclosporine 0.05% Eye Drops for Vernal Keratoconjunctivitis Trial","status":"COMPLETED","sponsor":"Second Affiliated Hospital of Nanchang University","startDate":"2020-07-01","conditions":"Vernal Keratoconjunctivitis, Cyclosporine 0.05% Eye Drops","enrollment":48},{"nctId":"NCT04708821","phase":"PHASE4","title":"DEXTENZA Therapy for Treatment of Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Clinical Research Center of Florida","startDate":"2021-04-30","conditions":"Bilateral Conjunctivitis (Disorder)","enrollment":31},{"nctId":"NCT04911361","phase":"PHASE4","title":"The DEPOT Study (Dry Eye Prescription Options for Therapy)","status":"COMPLETED","sponsor":"Research Insight LLC","startDate":"2021-08-10","conditions":"Dry Eye","enrollment":50},{"nctId":"NCT03123614","phase":"PHASE4","title":"Loteprednol vs. Prednisolone and Fluorometholone","status":"COMPLETED","sponsor":"University of Utah","startDate":"2014-09-19","conditions":"Intraocular Pressure, Corneal Opacity","enrollment":131},{"nctId":"NCT02813265","phase":"PHASE3","title":"Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Kala Pharmaceuticals, Inc.","startDate":"2016-06","conditions":"Dry Eye Syndromes, Keratoconjunctivitis Sicca","enrollment":918},{"nctId":"NCT02163824","phase":"PHASE3","title":"Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation","status":"COMPLETED","sponsor":"Kala Pharmaceuticals, Inc.","startDate":"2014-05","conditions":"Ocular Infections, Irritations and Inflammations","enrollment":380},{"nctId":"NCT02218489","phase":"PHASE2","title":"Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease","status":"COMPLETED","sponsor":"Kala Pharmaceuticals, Inc.","startDate":"2014-07","conditions":"Blepharitis","enrollment":206},{"nctId":"NCT02786901","phase":"PHASE3","title":"LE Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2016-06","conditions":"Cataract, Pain, Ocular Inflammation","enrollment":600},{"nctId":"NCT02188160","phase":"PHASE2","title":"Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Kala Pharmaceuticals, Inc.","startDate":"2014-06","conditions":"Dry Eye Syndromes, Keratoconjunctivitis Sicca","enrollment":150},{"nctId":"NCT02819284","phase":"PHASE3","title":"Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Kala Pharmaceuticals, Inc.","startDate":"2016-06","conditions":"Dry Eye Syndromes, Keratoconjunctivitis Sicca","enrollment":909},{"nctId":"NCT02793817","phase":"PHASE3","title":"Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain","status":"COMPLETED","sponsor":"Kala Pharmaceuticals, Inc.","startDate":"2016-06","conditions":"Post Surgical Ocular Inflammation and Pain","enrollment":520},{"nctId":"NCT02245516","phase":"NA","title":"Exploratory Study of KPI-121 Effect on Intra- or Subretinal Fluid Due to Retinal Vein Occlusion/Diabetic Macular Edema","status":"COMPLETED","sponsor":"Kala Pharmaceuticals, Inc.","startDate":"2014-07","conditions":"Retinal Vein Occlusion, Diabetic Macular Edema","enrollment":16},{"nctId":"NCT02208297","phase":"PHASE3","title":"Loteprednol Etabonate Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2014-09","conditions":"Inflammation, Pain, Cataract","enrollment":326},{"nctId":"NCT01996839","phase":"PHASE3","title":"Loteprednol Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2013-12","conditions":"Inflammation, Pain, Cataract","enrollment":514},{"nctId":"NCT00689078","phase":"PHASE4","title":"Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model","status":"COMPLETED","sponsor":"ORA, Inc.","startDate":"2008-05","conditions":"Allergic Conjunctivitis","enrollment":36},{"nctId":"NCT01437982","phase":"PHASE4","title":"A Study to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5%","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2010-08-05","conditions":"Conjunctivitis, Seasonal Allergic, Conjunctivitis, Giant Papillary, Inflammation","enrollment":140},{"nctId":"NCT03531697","phase":"PHASE1","title":"Study of Loteprednol Etabonate in Adults Undergoing Bilateral Cataract Surgery","status":"COMPLETED","sponsor":"Sandoz","startDate":"2018-04-26","conditions":"Inflammation Following Ocular Surgery","enrollment":381},{"nctId":"NCT04075227","phase":"PHASE4","title":"Topical 0.2% Loteprednol Etabonate vs. Topical 0.1% Dexamethasone in Impending Recurrent Pterygium","status":"COMPLETED","sponsor":"Wannisa Suphachearabhan","startDate":"2015-10-16","conditions":"Recurrent Pterygium of Eye, Steroid-Induced Glaucoma","enrollment":108},{"nctId":"NCT01817582","phase":"PHASE2","title":"Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease)","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2013-05-17","conditions":"Keratoconjunctivitis Sicca","enrollment":102},{"nctId":"NCT01443442","phase":"PHASE4","title":"Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Southern California College of Optometry at Marshall B. Ketchum University","startDate":"2011-10","conditions":"Allergic Conjunctivitis","enrollment":23},{"nctId":"NCT01749241","phase":"NA","title":"Efficacy of Loteprednol Ointment Following Eyelid Surgery","status":"WITHDRAWN","sponsor":"University of California, San Diego","startDate":"2012-09","conditions":"Post-operative Healing Following Blepharoplasty and Ptosis Repair","enrollment":""},{"nctId":"NCT01475643","phase":"PHASE3","title":"Loteprednol vs Prednisolone for the Treatment of Intraocular Inflammation Following Cataract Surgery in Children.","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2013-06","conditions":"Cataract","enrollment":107},{"nctId":"NCT01344226","phase":"","title":"Clinical Outcomes and Evaluation of Lotemax 0.5% in Treatment of Ocular Inflammation Associated With Cataract Surgery","status":"COMPLETED","sponsor":"Toyos Clinic","startDate":"2011-04","conditions":"Pseudophakia, Inflammation","enrollment":49},{"nctId":"NCT00366691","phase":"PHASE4","title":"Comparison of Acular LS With Lotemax to Prevent Inflammation After Cataract Surgery and Intraocular Lens Implantation","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2006-02","conditions":"Cataract Extraction","enrollment":40},{"nctId":"NCT03464435","phase":"PHASE4","title":"A Novel Combined Therapy for Refractory Vernal Keratoconjunctivitis","status":"COMPLETED","sponsor":"Zhongshan Ophthalmic Center, Sun Yat-sen University","startDate":"2016-11-01","conditions":"Vernal Keratoconjunctivitis","enrollment":20},{"nctId":"NCT01456780","phase":"PHASE4","title":"Efficacy of Zylet vs. Lotemax for the Treatment of Ocular Surface Inflammation/MGD/Blepharitis","status":"COMPLETED","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2011-08","conditions":"Meibomian Gland Dysfunction, Posterior Blepharitis","enrollment":60},{"nctId":"NCT01384266","phase":"","title":"A Comparison of 0.5% Loteprednol Etabonate Versus 1% Prednisolone Acetate Following Cataract Surgery","status":"COMPLETED","sponsor":"Associated Eye Care, Minnesota","startDate":"2010-05","conditions":"Intraocular Inflammation","enrollment":90},{"nctId":"NCT03098953","phase":"PHASE1","title":"Evaluation of the Safety, Systemic Pharmacokinetics, and Tolerability of Single and Repeat Ocular Installations","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2017-04-10","conditions":"Healthy","enrollment":15},{"nctId":"NCT03063489","phase":"PHASE1","title":"Evaluation of the Safety, Systemic Pharmacokinetics, and Tolerability","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2015-02","conditions":"Eye Pain","enrollment":15},{"nctId":"NCT02974387","phase":"PHASE4","title":"Safety and Efficacy of Lotemax Versus FML in Subjects Undergoing PRK for the Correction of Mild to Moderate Myopia, 3- Month Follow-up Study","status":"UNKNOWN","sponsor":"Dr Salouti Eye Research Center","startDate":"2017-04","conditions":"Must be PRK Candidate","enrollment":200},{"nctId":"NCT02825186","phase":"NA","title":"Dexamethasone (Sterodex) Versus Loteprendol (Lotemax) Eye Drops Following Strabismus Surgery","status":"UNKNOWN","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2016-07","conditions":"Ophthalmology","enrollment":100},{"nctId":"NCT02322528","phase":"NA","title":"Evaluation of Ocular Surface Inflammatory Mediators Effected by Lotemax","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2014-04","conditions":"Sjogren's Disease","enrollment":10},{"nctId":"NCT01695668","phase":"NA","title":"Treatment of Ocular Graft-versus-Host Disease (GVHD) With Topical Loteprednol Etabonate 0.5%","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2011-08","conditions":"Dry Eyes","enrollment":75},{"nctId":"NCT01853696","phase":"PHASE4","title":"Comparison of Corticosteroid Dosing Regimens After Endothelial Keratoplasty","status":"COMPLETED","sponsor":"Cornea Research Foundation of America","startDate":"2013-03","conditions":"Fuchs' Dystrophy, Corneal Edema","enrollment":167},{"nctId":"NCT00699153","phase":"PHASE3","title":"Loteprednol Etabonate in an Ophthalmic Base vs Vehicle for the Treatment of Inflammation Following Cataract Surgery","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2008-06","conditions":"Ocular Inflammation","enrollment":400},{"nctId":"NCT00645671","phase":"PHASE3","title":"Loteprednol Etabonate Ophthalmic Ointment vs. Vehicle in the Treatment of Inflammation Following Cataract Surgery","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2008-03","conditions":"Ocular Inflammation","enrollment":400},{"nctId":"NCT00705159","phase":"PHASE4","title":"Safety and Efficacy of Zylet vs Lotemax, Tobramycin and Vehicle in Pediatric Blepharoconjunctivitis","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2008-06","conditions":"Conjunctivitis","enrollment":137},{"nctId":"NCT02028312","phase":"PHASE4","title":"A Phase IV, Randomized, Parallel Group, Investigator-Masked Evaluation of the Effect of Loteprednol Etabonate Ophthalmic Gel 0.5% on the Initiation of Dry Eye Treatment With Restasis®","status":"WITHDRAWN","sponsor":"Edward Holland, MD","startDate":"2014-01","conditions":"Dry Eye Disease","enrollment":""},{"nctId":"NCT01721694","phase":"PHASE3","title":"Antibiotic Steroid Combination Compared With Individual Administration in the in the Treatment of Ocular Inflammation and Infection","status":"WITHDRAWN","sponsor":"Adapt Produtos Oftalmológicos Ltda.","startDate":"2012-12","conditions":"Ocular Inflammation, Infection Associated Blepharitis, Keratitis","enrollment":""},{"nctId":"NCT02218827","phase":"NA","title":"Topical Steroid Treatment For Dry Eye","status":"UNKNOWN","sponsor":"Meir Medical Center","startDate":"2014-09","conditions":"Dry Eye","enrollment":30},{"nctId":"NCT01724892","phase":"PHASE4","title":"Comparison the Effects of Dexamethasone and Loteprednol on Epithelial Healing","status":"COMPLETED","sponsor":"Khon Kaen University","startDate":"2012-11","conditions":"Epithelial Defect After Phototherapeutic Keratectomy","enrollment":32},{"nctId":"NCT01692652","phase":"NA","title":"Changes of Inflammatory Cytokines in the Tears of Moderate and Severe MGD Treated With Topical Loteprednol Etabonate","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2012-08","conditions":"Moderate and Severe Meibomiang Gland Dysfunction (Stage 3 or Stage 4 Meibomiang Gland Dysfunction)","enrollment":98},{"nctId":"NCT01736527","phase":"PHASE1","title":"Tear Fluid Levels of Loteprednol Etabonate Ophthalmic Gel 0.5% Following a Single Instillation","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2013-01","conditions":"Pharmacokinetics","enrollment":12},{"nctId":"NCT01193504","phase":"PHASE4","title":"Randomized, Masked Comparison of Bromfenac and Besifloxacin BID With Either Prednisolone BID or Loteprednol 0.5% BID for Prevention of Retinal Thickening and CME Following Phacoemulsification","status":"UNKNOWN","sponsor":"Innovative Medical","startDate":"2010-09","conditions":"Pseudophakia, Cataract Surgery","enrollment":100},{"nctId":"NCT01107405","phase":"PHASE2","title":"Loteprednol Ophthalmic Base Compared to Loteprednol Ophthalmic Suspension vs Placebo in an Allergen Challenge","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2010-04","conditions":"Allergic Conjunctivitis","enrollment":101},{"nctId":"NCT01435460","phase":"PHASE3","title":"Alrex® Versus Patanol in the Treatment of Seasonal Allergic Conjunctivitis(SAC)","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2010-08","conditions":"Seasonal Allergic Conjunctivitis","enrollment":300},{"nctId":"NCT01028027","phase":"PHASE3","title":"Loteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatment of Blepharokeratoconjunctivitis","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2009-10","conditions":"Conjunctivitis, Keratitis, Blepharitis","enrollment":357},{"nctId":"NCT01060072","phase":"PHASE3","title":"Evaluation of Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2010-02","conditions":"Inflammation, Pain","enrollment":407},{"nctId":"NCT01010633","phase":"PHASE3","title":"Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2009-11","conditions":"Inflammation, Pain","enrollment":406},{"nctId":"NCT00447577","phase":"PHASE4","title":"Zylet vs TobraDex in Blepharokeratoconjunctivitis","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2007-01","conditions":"Blepharokeratoconjunctivitis","enrollment":276},{"nctId":"NCT00532961","phase":"PHASE4","title":"Ocular Tolerance and Intraocular Pressure (IOP) Effects of Zylet Versus Tobradex","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2005-02","conditions":"Inflammation","enrollment":310},{"nctId":"NCT00420628","phase":"PHASE4","title":"Pediatric Zylet Safety and Efficacy Study","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2006-11","conditions":"Chalazion, Hordeolum","enrollment":108},{"nctId":"NCT00834171","phase":"","title":"A Retrospective Evaluation of the Intraocular Pressure Spikes With Loteprednol and Loteprednol/Tobramycin","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-01","conditions":"Ocular Hypertension","enrollment":50},{"nctId":"NCT00407043","phase":"PHASE4","title":"Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis","status":"COMPLETED","sponsor":"Ophthalmic Consultants of Long Island","startDate":"2006-11","conditions":"Dry Eye Disease, Keratoconjunctivitis Sicca","enrollment":5},{"nctId":"NCT00560638","phase":"PHASE2","title":"Loteprednol Etabonate Opthalmic Suspension for the Treatment of Dry Eye","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2005-11","conditions":"Dry Eye","enrollment":119},{"nctId":"NCT00817557","phase":"PHASE4","title":"Use of Loteprednol for Contact Lens Intolerance and Dryness","status":"UNKNOWN","sponsor":"Hom, Milton M., OD, FAAO","startDate":"2009-01","conditions":"Contact Lenses Dryness","enrollment":25},{"nctId":"NCT00781300","phase":"PHASE4","title":"Intraocular Pressure With Loteprednol and Dexamethasone","status":"COMPLETED","sponsor":"Federal University of São Paulo","startDate":"2006-03","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":35}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"PARANOIA"},{"count":1,"reaction":"PSYCHOTIC DISORDER"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Loteprednol (Lotemax)","genericName":"Loteprednol (Lotemax)","companyName":"Dr Salouti Eye Research Center","companyId":"dr-salouti-eye-research-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Loteprednol is a corticosteroid that suppresses inflammatory and immune responses in the eye by binding to glucocorticoid receptors. Used for Inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe, Post-operative inflammation following ocular surgery, Seasonal allergic conjunctivitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}